72 Countries and Over 6,000 Companies Participate in the Event
REV-MED Plans to Attend 25 International Conferences and Exhibitions in 2025
[Cultural News | Reporter Yonghoon Lee] REV-MED (CEO Edward BG Shin) successfully showcased its innovative products at MEDICA 2024, held in Düsseldorf, Germany, from November 11 to 14.
MEDICA is the world's largest medical device exhibition, featuring participation from 72 countries and over 6,000 companies, with approximately 80,000 visitors attending the event. REV-MED, a company renowned for its high export performance, has expanded its business from minimally manipulated biological medical devices to laser medical devices, gaining recognition both domestically and internationally.
At the exhibition, REV-MED introduced its flagship export products, including the TriCell PRP, NovaStem, PRP UNI, the aesthetic device ReWave, and the medical laser device Hilthera 4.0. Among these, the NovaStem kit, a Class III medical device developed with proprietary technology, concentrates biological substances through minimally invasive processing of autologous blood and bone marrow.
A company representative stated, "Participating in MEDICA 2024 allowed us to showcase our technological capabilities to buyers from around the globe, solidifying our position as a global leader in the bioindustry leveraging biological substances."
Looking ahead, REV-MED plans to participate in 25 international conferences and exhibitions in 2025.
Source: Cultural News https://www.mhns.co.kr/
[Cultural News | Reporter Yonghoon Lee] REV-MED (CEO Edward BG Shin) successfully showcased its innovative products at MEDICA 2024, held in Düsseldorf, Germany, from November 11 to 14.
MEDICA is the world's largest medical device exhibition, featuring participation from 72 countries and over 6,000 companies, with approximately 80,000 visitors attending the event. REV-MED, a company renowned for its high export performance, has expanded its business from minimally manipulated biological medical devices to laser medical devices, gaining recognition both domestically and internationally.
At the exhibition, REV-MED introduced its flagship export products, including the TriCell PRP, NovaStem, PRP UNI, the aesthetic device ReWave, and the medical laser device Hilthera 4.0. Among these, the NovaStem kit, a Class III medical device developed with proprietary technology, concentrates biological substances through minimally invasive processing of autologous blood and bone marrow.
A company representative stated, "Participating in MEDICA 2024 allowed us to showcase our technological capabilities to buyers from around the globe, solidifying our position as a global leader in the bioindustry leveraging biological substances."
Looking ahead, REV-MED plans to participate in 25 international conferences and exhibitions in 2025.
Source: Cultural News https://www.mhns.co.kr/